Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy
International Urology and Nephrology Oct 20, 2017
Wang J, et al. - In this study, alprostadil was tested for protective impacts on contrast-induced nephropathy (CIN) in type 2 diabetes mellitus (T2DM) patients treated with metformin after contrast media (CM) administration. In this patient population, CIN was better prevented by alprostadil hydration as compared with drinking water monohydration.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
